Edition:
United States

Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

9.44EUR
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
€9.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,365
52-wk High
€10.45
52-wk Low
€6.99

Latest Key Developments (Source: Significant Developments)

Vexim 9M sales rises to €13.3 million euros
Thursday, 13 Oct 2016 02:06am EDT 

Vexim SA :Vexim: +37% sales increase to 13.3 million euros ($14.90 million) as of september 30, 2016 (9 Months).  Full Article

Vexim Q3 revenue up 37 pct at 4.6 mln euros
Tuesday, 12 Jul 2016 12:05pm EDT 

Vexim SA : Q2 revenue 4.6 million euros ($5.1 million) versus 3.4 million euros year ago . H1 revenue 8.6 million euros versus 6.1 million euros year ago .At the end of the Q2 2016, total number of implants sold since launch of the SpineJack came to over 34,300 units.  Full Article

Vexim announces successful private placement of 10.4 mln euros
Thursday, 28 Jan 2016 01:00am EST 

Vexim SA:Announces success of its capital increase through a private placement of 10.4 million euros.Placed 1,269,694 new shares with a nominal value of 0.10 euros at unit price of 8.20 euros.  Full Article

Vexim initiates new clinical study on Spinejack
Tuesday, 12 Jan 2016 02:00am EST 

Vexim SA:Initiates a new clinical study to support safety, efficacy and cost-effectiveness of Spinejack compared to conservative treatment.  Full Article

Vexim SA announces nomination of Steve Swinson as new chairman of board
Monday, 30 Nov 2015 02:00am EST 

Vexim SA:Says nomination of Steve Swinson as new chairman of board of directors.  Full Article

Vexim SA initiates international clinical study with first patient treated to support planned 510(k) application to market SpineJack
Thursday, 4 Jun 2015 01:00am EDT 

Vexim SA:Says the initiation of a new clinical study intended to support the company's application for 510(k) regulatory clearance to market SpineJack in the U.S.  Full Article

Vexim reports excellent 1 yr results of comparative randomized study of Spinejack versus Balloon Kyphoplasty
Friday, 17 Apr 2015 01:00am EDT 

Vexim SA:Vexim reports 1-year results of comparative randomized study of Spinejack versus Balloon Kyphoplasty.Says results of a pilot feasibility study were excellent.Study compares safety and performances of Spinejack to Medtronic Balloon in treatment of vertebral compression fractures in patients with osteoporosis.  Full Article

Vexim SA gives FY 2015 profit guidance
Tuesday, 24 Mar 2015 03:00am EDT 

Vexim SA:Expects to reach profitability during the course of FY 2015.  Full Article

Vexim SA obtains CE approval to market MasterflowTM Injection system in Europe
Tuesday, 10 Mar 2015 03:00am EDT 

Vexim SA:Announced the grant of the European CE approval of Masterflow(TM1), a fully integrated system for mixing and injecting orthopedic cement for vertebral augmentations.  Full Article

Vexim SA announces a long term performances of SpineJack supported by 24-month follow-up clinical study
Monday, 2 Mar 2015 02:00am EST 

Vexim SA:Says 2-year results of study on 103 patients confirm already demonstrated excellence of SpineJack1 at the 1-year follow-up in treating acute fresh traumatic vertebral compression fractures.Says prospective, observational and consecutive study involved 14 clinical investigating sites located in France, Germany, Switzerland, Spain, Italy and Austria.103 patients were recruited in this study with high rate of complex fractures.Results revealed statistically significant advantages of SpineJack in terms of patient's pain, function and quality of life over 1 and 2 years post-surgery.Vertebral pain was assessed using Visual Analog Scale (VAS), and showed significant 82 pct average decrease in pain at 1 year (79 pct at post op).Improvement was sustained over the 2-year follow-up period with a decrease of 85 pct at 2 years.In addition, decrease in pain allowed a strong reduction in the consumption of analgesics. 2 years after the surgery, 98.3 pct of patients were using no medication at all or mild analgesic.  Full Article

BRIEF-Vexim 9M sales rises to 13.3 million euros

* Vexim: +37% sales increase to 13.3 million euros ($14.90 million) as of september 30, 2016 (9 Months) Source text: http://bit.ly/2dZfG5L Further company coverage: ($1 = 0.8928 euros) (Gdynia Newsroom)